Rossari Biotech reports strong Q2, H1 FY26 performance with revenue and profit growth

Rossari Biotech Limited reported an 18% year-over-year increase in Q2 FY26 revenues to INR 586.1 crore, with EBITDA growing 9% to INR 71.9 crore and PAT rising 5% to INR 36.9 crore. For H1 FY26, revenues reached INR 1,129.8 crore, up 14% year-over-year, while EBITDA increased 7% to INR 139.7 crore and PAT saw a marginal rise of 0.4% to INR 70.5 crore. The company's HPPC, TSC, and AHN businesses were key drivers, growing 16%, 21%, and 29% respectively in Q2 FY26.

Exports showed robust growth of 36% year-over-year in Q2 and 27% in H1, contributing almost 28% of overall sales. The company successfully commissioned an additional 20,000 MTPA capacity at its Dahej facility, bringing total installed capacity to 1,52,500 MTPA, and 15,000 MTPA ethoxylation capacity at Unitop, reaching 51,000 MTPA. An investment of up to USD ~8 million was approved for Rossari International Limited Company in Saudi Arabia to enhance global presence.

The company's earnings presentation highlighted its "Strong Quarterly Performance" with highest quarterly revenue, EBITDA, and PAT. HPPC contributed 78% of the business sector revenue in Q2 FY26. Efforts in institutional and B2C businesses narrowed losses, reflecting ongoing optimization.